This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Further information

MYOCARDITIS
Wang Y, Chen W, Li M, Chen X
OBJECTIVE: To analyze the therapeutic effect of captopril combined with phosphocreatine sodium in patients with viral myocarditis. METHODS: A total of 140 patients with infectious myocarditis who received treatment in Hanzhong City People's Hospital from December 2019 to January 2022 were retrospectively enrolled as study subjects. 61 of them were treated with captopril and constituted the control group (CG), and the remaining 79 who received phosphocreatine sodium in addition to captopril were the research group (RG). Variables were observed and compared between the two groups, including clinical efficacy, adverse reactions during treatment, and changes in myocardial enzymes, cardiac function, troponin, and inflammatory factors. According to therapeutic effect, those patients with marked results were categorized as the significant improvement group, and those whose results were just effective or ineffective were the insignificant improvement group. The risk factors affecting the efficacy of the patients were analyzed by logistic regression. RESULTS: Compared to the CG, the RG had greater decreases in aspartate aminotransferase (AST), creatine kinase isoenzyme (CK-MB), creatine kinase (CK), and lactate dehydrogenase (LDH) (all P < 0.05). The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (FS), and left ventricular stroke volume (SV) in the RG increased significantly more after treatment (P < 0.05), while the levels of high-sensitivity troponin I (cTnI) and cardiac troponin T (cTnT) decreased more significantly (P < 0.05) compared to the CG. The levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in the RG were more down-regulated (P < 0.05), and they had a higher overall response rate after treatment (P < 0.05). However, there was no significant difference in the incidence of adverse reactions between these two groups (P > 0.05). Multivariate logistic regression analysis showed that CK-MB, LVEF, cTnI, and cTnT were independent factors affecting the efficacy. CONCLUSION: Captopril combined with phosphocreatine sodium can reduce the inflammatory response in patients with infectious myocarditis, improve cardiac function, and improve the therapeutic efficacy.
12/01/2023
36628215
American journal of translational research (IF: 3.94 / Quartile: )
WOS Cites:
SemanticScholar Cites: 0
SemanticScholar Citation Velocity: 0
SemanticScholar Influential Citation Count: 0
Only annotations in title abstract:
YES

Data Sources

IMIB-Arrixaca

Address

Biomedical Informatics & Bioinformatics Platform
Institute for Bio-health Research of Murcia (IMIB-Arrixaca)
Carretera Buenavista s/n, 30120
El Palmar, Murcia, Spain

Phones

+34 968885229
+34 968885239
+34 968885249